Cagrilintide

Metabolic In trials Human trials

A long-acting copy of amylin, a hormone released with insulin after meals. A fatty-acid side chain lets it bind albumin and last about a week. It acts on amylin and calcitonin receptors in the brainstem to increase fullness and slow stomach emptying, and is studied for weight management, often together with semaglutide.

Evidence at a glance

Evidence: Human trials — Studied in people
Status: Reached clinical trials
Dosing: A dose has been tested in humans

Nausea and vomiting are common. Still investigational.

What studies report

Around 10-11% body weight loss over a year on its own in phase 2
About 20%+ when combined with semaglutide (CagriSema) in phase 3
Reduced appetite and slower gastric emptying

How it works

Activates amylin receptors — calcitonin receptors paired with receptor activity-modifying proteins — in the brainstem. That increases fullness, slows stomach emptying and reduces glucagon after meals. A fatty acid chain binds it to albumin so it lasts about a week.

Binds a receptor on the cell surface and signals inward

Where it acts

Pancreas

The library groups this compound under Metabolic. The diagram shows that target, not every tissue it reaches.

Illustrated

Human pancreatic islets among acinar tissue, cellular close-up with distinguishable endocrine cells.

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Appetite suppression and weight lossBlood sugar control

Reasons people seek it out — not a list of proven effects.

In practice Unapproved use

Appearing through compounding pharmacies and research suppliers ahead of approval
Stacked with semaglutide or tirzepatide, mirroring the CagriSema trials
Sold pre-blended with semaglutide in a single vial, the combination tested as CagriSema

Science hasn't caught up: Being used in combination ahead of the approval its combination trials are still seeking.

Reported real-world use, not evidence and not a recommendation.

Dosing

What was tested Evidence

0.3–4.5 mg weekly, subcutaneous26 weeksPhase 2 obesity trial→ Up to ~10–11% weight loss at the highest dose
2.4 mg weekly with semaglutide 2.4 mg68 weeksCagriSema phase 3→ Over 20% weight loss

What people report using Not evidence

Titrated upward weekly, following the trial schedule

Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.

Status: In late-stage clinical trials. Not approved as of this writing.

Route: Subcutaneous injection, from reconstituted lyophilised powder
Molecular weight: ≈4409 g/mol
CAS: 1415456-99-3
Available as: 5 mg, 10 mg

Search PubMed for Cagrilintide → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.